Ambrx Biopharma Inc - ADR Aktie News

SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., (“Ambrx” or the “Company”) (NASDAQ: AMAM), today announced that its shareholders approved a proposal to adopt the merger agreement entered into between the Company and Johnson & Johnson at its Special Meeting of Shareholders. As previously announced, under the terms of the transaction, Ambrx shareholders will receive $28.00 pe...

With stocks up 200%, you face a dilemma. While you don't want to fight momentum, you also don't want to buy into excessive exuberance and jump into a stock at its top, forced to hold until break-even or sell for a loss down the road.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Ambrx Biopharma, Inc. (NasdaqGS: AMAM) to Johnson & Johnson (NYSE: JNJ). Under the terms of the proposed transaction, shareholders of Ambrx will receive $28.00 in cash for each share of Ambrx that they own. KSF is...

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Ambrx Biopharma, Inc. (NasdaqGS: AMAM) to Johnson & Johnson (NYSE: JNJ). Under the terms of the proposed transaction, shareholders of Ambrx will receive $28.00 in cash for each share of Ambrx that they own. KSF is...

Shares of engineered therapeutics specialist Ambrx Biopharma (NASDAQ: AMAM ) skyrocketed on Monday following a major announcement. Pharmaceutical and medical technology stalwart Johnson & Johnson (NYSE: JNJ ) will buy out the company, which should strengthen its oncology unit.

The deal, which was announced on the first day of the annual JPMorgan Healthcare Conference, makes J&J the latest drugmaker to bet on ADCs.

Shares of Ambrx Biopharma Inc (NASDAQ: AMAM) roughly doubled this morning after Johnson & Johnson (NYSE: JNJ) revealed plans of acquiring the clinical-stage biopharmaceutical company. Details of the JNJ-Ambrx deal Johnson & Johnson is willing to pay about $2.0 billion to buy the Nasdaq-listed firm.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Ambrx Biopharma, Inc. (NASDAQ: AMAM) to Johnson & Johnson for $28.00 per share in cash is fair to Ambrx shareholders. Halper Sadeh encourages Ambrx shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 ...